Coherus Oncology (CHRS) Tax Rate (2019 - 2023)

Coherus Oncology (CHRS) reported Tax Rate of 0.95% for Q3 2023, down 90.29% sequentially from 9.78% in Q4 2020.

Coherus Oncology (CHRS) Tax Rate (2019 - 2023) Analysis & Trends

Coherus Oncology (CHRS) has 3 years of Tax Rate data on file, last reported at 0.95% in Q3 2023.

For the quarter ending Q3 2023, Tax Rate changed N/A year-over-year to 0.95%; the trailing twelve-month figure through Dec 2023 stood at 0.16% (changed N/A YoY), and the FY2024 full-year result was 0.05%, down 21.0% from the prior year.
Tax Rate eased to 0.95% in Q3 2023, from 9.78% in the prior quarter.
In the past five years, Tax Rate ranged from a high of 9.78% in Q4 2020 to a low of 0.22% in Q2 2019.
A 3-year average of 2.85% and a median of 1.91% in 2019 frame the typical range for Tax Rate.
Peak annual rise in Tax Rate reached 493 bps in 2020, while the deepest fall reached 102 bps in 2020.
Tracing CHRS's Tax Rate over 3 years: stood at 4.85% in 2019, then surged by 102 bps to 9.78% in 2020, then tumbled by 90 bps to 0.95% in 2023.
Business Quant data shows CHRS's Tax Rate at 0.95% in Q3 2023, 9.78% in Q4 2020, and 0.65% in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Tax Rate (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-0.34
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	5.61
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	12.29
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	17.68
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	12.51
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	-13.70
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-
10	Coherus Oncology	194.37 Mn	27.32 Mn	8.50 Mn	-

Download Data